Dynavax Names William J. Dawson Vice President, Finance and Operations, and Chief Financial Officer
Contact:
Dynavax Technologies Corporation
Dino Dina, M.D.
President and CEO
510-848-5100
Berkeley, CA -- August 22, 2002 - Dynavax Technologies Corporation today announced the appointment of William J. Dawson to the position of vice president, finance and operations, and chief financial officer.
Mr. Dawson was most recently corporate senior vice president, business development, for McKesson Corporation (NYSE: MCK), where he was responsible for mergers and acquisitions and venture capital investing for the San Francisco-based healthcare services company. He was also acting chief financial officer of iMcKesson, a wholly-owned e-health subsidiary of McKesson with $300 million in revenue. Prior to McKesson, Mr. Dawson was a managing director in corporate finance at Volpe Brown Whelan LLP, where he specialized in biopharmaceutical companies, and at Kemper Securities, and a senior vice president at Sutro & Co. for a cumulative total of 15 years. Mr. Dawson earned his A.B. in mechanical engineering from Stanford University and an MBA from Harvard Business School.
Dynavax Technologies is a privately held biopharmaceutical company developing innovative products to treat allergy, inflammation-mediated diseases, infectious diseases and cancer. The company's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to fight disease and prevent inflammation. ISS is in four different clinical trials, including ragweed allergy, hepatitis B, asthma and cancer. In addition, Dynavax is developing an oral TNF-alpha synthesis inhibitor, initially for the treatment of rheumatoid arthritis. A company profile is available at the Dynavax website at www.dynavax.com.